

## ChemDiv Incorporated

[View the current ChemDiv Incorporated Page on BioPortfolio.com](http://www.bioportfolio.com/biocorporate/2660-ChemDiv+Incorporated.html)

(<http://www.bioportfolio.com/biocorporate/2660-ChemDiv+Incorporated.html>)

### Contact Details:

11575 Sorrento Valley Road Suite 210

San Diego

CA

92121

United States of America

Tel: 619 794 4860

Fax: 619 794 4931

Email:

### Recent Publications by ChemDiv Incorporated:



- [Synthesis and Biological Evaluation of Novel 5.8-Disubstituted-2-methyl-2,3,4,5-tetrahydro-1H-pyrido\[4.3-b\] indoles as 5-HT\(6\) and H\(1\) Receptors Antagonists.](#)  
*Synthesis, biological evaluation, and structure-activity relationships...* 19th November, 2009  
ChemDiv, Inc., San Diego, CA, USA.- Arch Pharm (Weinheim). 2009 Nov 17;342(12):740-747. ([DOI Direct Link](#))
- [Computational mapping tools for drug discovery.](#)  
*During the past decade, computational technologies have become well...* 21st October, 2009  
ChemDiv Inc., 6605 Nancy Ridge Drive, San Diego, CA 92121, USA.- Drug Discov Today. 2009 Aug;14(15-16):767-75. Epub 2009 Jun 9. ([DOI Direct Link](#))
- [Discovery and potency optimization of 2-amino-5-arylmethyl-1,3-thiazole derivatives as potential therapeutic agents for prostate cancer.](#)  
*A new chemical series was identified via high-throughput screening as...* 15th September, 2009  
Department of Lead Discovery, Chemical Diversity Research Institute,- Arch Pharm (Weinheim). 2009 Jul;342(7):420-7. ([DOI Direct Link](#))
- [Compound library design for target families.](#)  
*Chemogenomics is a modern approach to analysis of the biological effect of...* 4th September, 2009  
ChemDiv, Inc., San Diego, CA, USA.- Methods Mol Biol. 2009;575:21-46. ([DOI Direct Link](#))
- [Synthesis and biological evaluation of novel gamma-carboline analogues of Dimebon as potent 5-HT6 receptor antagonists.](#)  
*Synthesis, biological evaluation and structure-activity relationships for...* 22nd August, 2009

Department of Organic Chemistry, Chemical Diversity Research Institute, - Bioorg Med Chem Lett. 2009 Jun 15;19(12):3183-7. Epub 2009 May 3. ([DOI Direct Link](#))

- [Imidazo\[1,2-a\]quinoxalines accessed via two sequential isocyanide-based multicomponent reactions.](#)  
*A novel synthetic protocol toward imidazo[1,2-a]quinoxalines has been...* 1st May, 2009  
Chemical Diversity Research Institute, 2a Rabochaya Street, Khimki, Moscow- J Org Chem. 2009 Mar 20;74(6):2627-9. ([DOI Direct Link](#))
- [New approaches to the treatment of inflammatory disease : focus on small-molecule inhibitors of signal transduction pathways.](#)  
*This 'state-of-the-art' review specifically focuses on alternative...* 20th February, 2009  
ChemDiv, Inc., San Diego, California, USA.- Drugs R D. 2008;9(6):397-434. doi: 10.2165/0126839-200809060-00005.
- [CXCR4 receptor as a promising target for oncolytic drugs.](#)  
*There has been considerable in vivo evidence that chemokine receptor CXCR4...* 6th November, 2008  
Small Molecule Drug Discovery, ChemDiv, Inc., San Diego, California 92121,- Mini Rev Med Chem. 2008 Oct;8(11):1075-87.
- [Regulators of chemokine receptor activity as promising anticancer therapeutics.](#)  
*Chemokines are a family of small proteins inducing directed cell migration...* 12th August, 2008  
ChemDiv,- Curr Cancer Drug Targets. 2008 Jun;8(4):299-340.
- [Caspase activity modulators as anticancer agents.](#)  
*Proteolytic caspase enzymes play a central role in cell apoptosis, or...* 16th May, 2008  
ChemDiv,- Anticancer Agents Med Chem. 2008 Apr;8(3):322-41.
- [Novel mitotic targets and their small-molecule inhibitors.](#)  
*With several successful anticancer drugs on the market and numerous...* 13th February, 2008  
ChemDiv, Inc. 11558 Sorrento Valley Rd., Ste. 5, San Diego, CA 92121, USA.- Curr Cancer Drug Targets. 2007 Dec;7(8):766-84.
- [Histone deacetylase inhibitors in cancer therapy: latest developments, trends and medicinal chemistry perspective.](#)  
*Regulation of gene expression is mediated by several mechanisms such as...* 6th November, 2007  
ChemDiv, Inc. 6605 Nancy Ridge Dr. San Diego, CA 92121, USA.- Anticancer Agents Med Chem. 2007 Sep;7(5):576-92.
- [Small-molecule modulators of Hh and Wnt signaling pathways.](#)  
*Hedgehog (Hh) and Wnt signaling pathways play key roles in growth and...* 11th September, 2007  
Small Molecule Drug Discovery, ChemDiv, Inc., San Diego, CA 92121, USA.- Expert Opin Ther Targets. 2007 Aug;11(8):1087-101. ([DOI Direct Link](#))
- [Novel inhibitors of VEGF receptors-1 and -2 based onazole-5-carboxamide templates.](#)  
*We have developed a series of novel potent...* 7th September, 2007  
Small Molecule Drug Discovery, Chemical Diversity, Inc., 11558 Sorrento- Bioorg Med Chem Lett. 2007 Jul 1;17(13):3550-7. Epub 2007 Apr 22. ([DOI Direct Link](#))
- [1H-1,2,4-triazol-3-yl-anilines: novel potent inhibitors of vascular endothelial growth factor receptors 1 and 2.](#)  
*Novel derivatives of 1,2,4-triazoles are described as potent...* 18th July, 2007  
ChemDiv Inc., 6605 Nancy Ridge Drive, San Diego, CA 92121, USA.- Chem Biol Drug Des. 2007 May;69(5):331-7. ([DOI Direct Link](#))

**Press Releases on ChemDiv Incorporated:**

<a href="#">Reportlinker Adds Blood Banking and Blood Products - Global Market Perspective</a>	25th November, 2009	Reportlinker	NEW YORK, Nov. 25 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: Blood Banking and Blood Products - Global Market Perspective <a href="http://www">http://www</a>
<a href="#">Quest Diagnostics To Speak At The 21st Annual Piper Jaffray Healthcare Conference</a>	24th November, 2009	Quest Diagnostics	MADISON, N.J., Nov. 24 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced that it is
<a href="#">Prodesse's ProParaflu+(TM) Assay Cleared for US Marketing by FDA</a>	24th November, 2009	Gen-Probe Incorporated	Michael Watts Vice president, investor relations and corporate communications 858-410-8673 SOURCE Gen-Probe Incorporated
<a href="#">Aflac To Exchange Two Lloyds Banking Group Securities. Enhance Risk-Based Capital Ratio</a>	24th November, 2009	Aflac Incorporated	COLUMBUS, Ga., Nov. 24 /PRNewswire-FirstCall/ -- Aflac Incorporated (NYSE: AFL) announced today that the Lloyds Banking Group plc has accepted the exchange of two of its investment securities owned by
<a href="#">WellTek Positioned to Capitalize on Trends in Health and Fitness</a>	24th November, 2009	WellTek Incorporated	ORLANDO, Fla., Nov. 24 /PRNewswire-FirstCall/ -- Two thirds of adults are overweight and one third of those are obese. Experts estimate that 80 percent of the population will experience a back

## BioNews Results for ChemDiv Incorporated



- [Neuronascent Announces Collaboration with ChemRar for Characterization of Developmental Pathway Inhibitors Usi](#)  
*PR Newswire: Nov 8 2009 5:58PM Matching: chemdiv*
- [Neuronascent Announces Collaboration With ChemRar For Characterization Of Developmental Pathway Inhibitors Usi](#)  
*Drug Discovery Online: Nov 5 2009 4:13AM Matching: chemdiv*
- [Neuronascent Announces Collaboration with ChemRar for Characterization of Developmental Pathway](#)

## [Inhibitors Usi](#)

*KOTA Territory News: Nov 4 2009 11:16PM Matching: chemdiv*

- [Neuronascent Announces Collaboration with ChemRar for Characterization of Developmental Pathway](#)

## [Inhibitors Usi](#)

*Pharma Live: Nov 4 2009 8:46PM Matching: chemdiv*

- [Neuronascent Announces Collaboration with ChemRar for Characterization of Developmental Pathway](#)

## [Inhibitors Usi](#)

*Montana's News Station: Nov 4 2009 7:26PM Matching: chemdiv*

- [Neuronascent Announces Collaboration with ChemRar for Characterization of Developmental Pathway](#)

## [Inhibitors Usi](#)

*Freshnews.com: Nov 4 2009 5:13PM Matching: chemdiv*

- [Neuronascent Announces Collaboration with ChemRar for Characterization of Developmental Pathway](#)

## [Inhibitors Usi](#)

*Genetic Engineering News: Nov 4 2009 4:24PM Matching: chemdiv*

- [Viriom Selects ChemDiv To Develop HIV Program](#)

*MediLexicon: Oct 20 2009 5:39AM Matching: chemdiv*

- [Medical News: Viriom Selects ChemDiv To Develop HIV Program](#)

*Medical News Today: Oct 19 2009 11:51PM Matching: chemdiv*

- [ChemDivEURs Russian arm wins Viriom HIV research contract](#)

*Outsourcing Pharma: Oct 20 2009 12:30PM Matching: chemdiv*

- [ChemDivEURs Russian arm wins Viriom HIV research contract](#)

*Outsourcing Pharma: Oct 20 2009 12:29PM Matching: chemdiv*

- [Viriom Selects ChemDiv to Develop HIV Program](#)

*Freshnews.com: Oct 19 2009 8:10AM Matching: chemdiv*

- [Viriom Selects ChemDiv To Develop HIV Program](#)

*Medical News Today: Oct 19 2009 9:14PM Matching: chemdiv*

- [Viriom Selects ChemDiv to Develop HIV Program](#)

*Pharmacy Choice: Oct 19 2009 2:31PM Matching: chemdiv*

- [Viriom Selects ChemDiv to Develop HIV Program](#)

*Research & Development: Oct 19 2009 9:49AM Matching: chemdiv*

## **BioCorporate Profiles - upgrade to a full profile**

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services.

BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

\*\*\*

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

